drugset / Trial / NCT03239145
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Phase 1
Completed
62 enrolled
Dana-Farber Cancer Institute
Amgen · collabMerck Sharp & Dohme LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: * Pembrolizumab * AMG386
Timeline
- Start
- 2018-05-01
- Primary completion
- 2024-12-13
- Completion
- 2024-12-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Trebananib | Peptide | 15 mg/kg | Intravenous |
| Subject | Trebananib | Peptide | 30 mg/kg | Intravenous |